| June 2 |
Acorda Therapeutics Announces Positive Data from Second Phase 3
Study of Fampridine-SR on Walking Ability in People with Multiple
Sclerosis |
| June 2 |
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX
GM-CSF in Metastatic Melanoma at the 2008 American Society of
Clinical Oncology Meeting |
| June 2 |
Apthera's NeuVax Produces Delays in Recurrence in High-Risk
HER2-Positive Prostate Cancer Patients |
| June 2 |
Antisoma plc (UK) - Positive data on Antisoma's ASA404 presented at
ASCO |
| June 2 |
CuraGen Announces Data From Ongoing Phase I/II Trial Showing
Clinical Activity of CR011-vcMMAE in Metastatic Melanoma |
| June 2 |
Clavis Pharma ASA (NO) - Elacyt Clinical Results Presented at ASCO |
| June 2 |
Data from Satraplatin SPARC Phase 3 Trial in Patients with
Hormone-Refractory Prostate Cancer Progressing after Initial
Chemotherapy Presented at 44th ASCO Annual Meeting |
| June 2 |
Data Presented at ASCO Identify Maximum Tolerated Dose and Confirm
c-Met Inhibition in Tumors with ARQ 197, Under Development by
ArQule |
| June 2 |
Data Confirm Avastin Helps Patients With Metastatic Colorectal
Canc... |
| June 2 |
Data To Be Presented at ASCO Supports Potential of Peregrine's
Cotara for the Treatment of Brain Cancer |
| June 2 |
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved
Progression-Free Survival in Women with Advanced HER2-Negative
Breast Cancer |
| June 2 |
YM Biosciences Reports Nimotuzumab Nsclc Clinical Data at ASCO
Annual Meeting |
| June 2 |
Velcade (Bortezomib) for Injection Based Treatment Delivers
Impressive Complete Response and Survival in Patients With Newly
Diagnosed Multiple Myeloma |
| June 2 |
Video: Major Independent Trial Demonstrates Significant Anticancer
Benefit of Zometa in Women With Early-Stage Breast Cancer |
| June 2 |
Vion Pharmaceuticals Announces Presentation of Data from Phase III
Trial of Cloretazine (VNP40101M) and Cytarabine in Relapsed Acute
Myelogenous Leukemia at the ASCO Annual Meeting |
| June 2 |
Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO |
| June 2 |
Updated Data from Ongoing Phase 3 Trials Support the Continued
Study of Vectibix (panitumumab) in Combination with Standard
Chemotherapy |
| June 2 |
Combination Therapy of Solvent-free Abraxane and the Targeted
Therapy Bevacizumab Evaluated as First-line Treatment for
Metastatic Breast Cancer |
| June 2 |
Updated Revlimid Results Presented In Relapsed/Refractory
Aggressive Non-Hodgkin's Lymphoma (NHL) at ASCO |
| June 2 |
Transgene’s Therapeutic Vaccine TG4010 Meets Primary Endpoint
in Non-small Cell Lung Cancer Phase IIb Trial |
| June 2 |
ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with
Targeted Anticancer Compounds IMGN242 and AVE1642 |
| June 2 |
Preliminary Data from Ongoing Phase 1 Data of Investigational
Anti-PD-1 Antibody Presented at American Society of Clinical
Oncology Annual Meeting |
| June 2 |
Novo Nordisk and Neose Announce Completion of Initial Phase 1
Clinical Trial of NN7128 (Long-Acting Factor VIIa) |
| June 2 |
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO |
| June 2 |
Cell Genesys Reports Updated Results From Phase 1 Clinical Trial of
GVAX Immunotherapy for Prostate Cancer Used in Combination With
Ipilimumab |
| June 2 |
Data from Satraplatin SPARC Phase 3 Trial in Patients with
Hormone-Refractory Prostate Cancer Progressing after Initial
Chemotherapy Presented at 44th ASCO Annual Meeting |
| June 2 |
EntreMed's ENMD-2076 Demonstrates Antitumor Activity in Multiple
Myeloma Model |
| June 2 |
Genta Announces Initial Clinical Trial Results for G4544, a Novel
Potent Drug for Bone Disease |
| June 2 |
Quest PharmaTech Announces Positive Results from Phase I Clinical
Trial of its Photodynamic Therapy for Actinic Keratosis |
| June 2 |
PsychoGenics Announces Positive Phase-IIa for Its First-in-Class
Partial 5-HT1A - 5-HT1B Receptor Agonist in ADHD |
| June 2 |
Sanofi-aventis and Oxford Biomedica Report Encouraging Trovax Phase
II Trial Results in Metastatic Renal Cancer |
| June 2 |
Gloucester Pharmaceuticals Announces Presentation of Romidepsin
Phase 1 Data in Multiple Solid Tumors at ASCO |
| June 2 |
Adherex Announces Updated ADH-1 Chemotherapy Combination Data in
Melanoma |
| June 2 |
Curis Announces GDC-0449 Phase I Clinical Data Presented at
American Society of Clinical Oncology Annual Meeting 2008 |
| June 2 |
New Data Show Patients Using Avonex Reported Less Sick Leave and
Short-Term Disability Costs Than Patients Using Copaxone |
| June 2 |
CytRx to Present Favorable Study Data with Iroxanadine in Diabetic
Wound Healing at the Third Congress of the World Union of Wound
Healing Societies |
| June 2 |
New Positive Data Announced for NKTR-102 (PEG-irinotecan),
Highlights Promise of Nektar's Innovative Small Molecule
PEG-Oncolytics |
| June 2 |
Oculus Innovative Sciences Announces Market Assessment of Near-Term
Commercialization Opportunities in the United States for Dermacyn
Wound Care |
| June 2 |
Jennerex Clinical Trial Data with JX-594 Selected for Plenary
Session Presentation at Major International Conference |
| June 2 |
Isis' Partners Present Clinical Data on Antisense Drugs at the
American Society of Clinical Oncology |
| June 2 |
Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO |
| June 2 |
Combination Therapy of Solvent-Free Abraxane and the Targeted
Therapy Bevacizumab Evaluated as First-Line Treatment for
Metastatic Breast Cancer |
| June 2 |
Abraxane in Combination with Trastuzumab and Carboplatin Evaluated
as First-Line Treatment for Patients with HER2-Positive Metastatic
Breast Cancer |
| June 2 |
VioQuest Pharmaceuticals Presents Phase 1 Data Showing Promising
Immune Response and Safety Profile of Lenocta |
| June 2 |
Incyte's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits
in Ongoing Phase I/II Myelofibrosis Study |
| June 2 |
TransMolecular Reports Positive Results from Phase 1 Trial of
(131)Iodine-TM601 in Metastatic Melanoma |
| June 2 |
Molecular Insight Pharmaceuticals, Inc. Reports Preliminary Results
of Azedra Phase I Trial in Neuroendocrine Cancer Patients at ASCO |
| June 2 |
Research Explains How Advanced Prostate Cancer Becomes Resistant to
Androgen-Deprivation Therapy |
| June 2 |
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and
Tolerability in Systemic Treatment of Pancreatic Carcinoma,
Malignant Melanoma and Colorectal Carcinoma |
| June 2 |
Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in
Phase Iib EMEA provides Guidance on Phase III Design and Approval
Requirements |
| June 2 |
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable
Complete Remissions in Secondary AML |
| June 2 |
Lung Cancer Alliance Hails Announcement of New Erbitux Data |
| June 2 |
Novelos Announces Presentation of Encouraging Results in Phase 2
Ovarian Cancer Trial at 2008 ASCO Meeting by MGH and
Dana-Farber/Harvard Cancer Centers |
| June 2 |
New Nexavar Data Presented in Multiple Tumor Types at 44th American
Society of Clinical Oncology Annual Meeting |
| June 2 |
Schering-Plough's Sugammadex Provides Fast Reversal of Effects of
Muscle Relaxants Used in General Anesthesia |
| June 2 |
IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is
Well Tolerated With Positive Survival Trend in Non-Small Cell Lung
Cancer Patients |
| June 2 |
University of Miami Team Confirms Value of Monitoring Cell-Mediated
Immunity Pre- and Post-Transplant in Management of Kidney
Transplant Recipients |
| June 2 |
Study Suggests Survival Benefit from Radioactive Microsphere
Therapy in Patients with Colorectal Cancer Liver Metastases who
have Failed Chemotherapy |
| June 2 |
Further Clinical Testing of BZL101 in Advanced Breast Cancer
Demonstrates Favorable Efficacy and Toxicity Profiles |
| June 2 |
Stimuvax Phase 1/2 Survival Data Support Prior Results |
| June 2 |
New Publication of Phase 2 Data Shows Maribavir Markedly Reduced
the Rate of Cytomegalovirus Infection and Disease in Bone Marrow
Transplant Patients |
| June 2 |
BiPar Sciences Presents Initial Clinical Data of BSI-201, a Novel
DNA Repair Inhibitor |
| June 2 |
Researchers at Signature Characterize Previously Unreported
Microduplication |
| June 2 |
Ipsen and Spirogen's SJG-136 Shows Encouraging Results in the
Treatment of Refractory Solid Tumours At ASCO |
| June 2 |
OncoGenex Reports that Low Serum Clusterin Levels were Predictive
of Survival in Preliminary Analyses of Phase 2 Study of Lead Drug
Candidate OGX-011 |
| June 2 |
Keryx Biopharmaceuticals, Inc. Announces Poster Presentation
Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at
the American Society of Clinical Oncology Meeting in Chicago,
Illinois |
| June 2 |
Geron Presentations at the ASCO 2008 Annual Meeting |
| June 2 |
Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th
Annual ASCO Annual Meeting |
| June 2 |
Vidaza Data Presented at ASCO Demonstrates Significant Overall
Survival for Myelodysplastic Syndrome Patients |
| June 2 |
Metformin Increases Pathologic Complete Response Rates in Breast
Cancer Patients With Diabetes |
| June 2 |
Hana Reports Progress in Phase 2 Uveal Melanoma Trial |
| June 2 |
Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate)
Phase I and Phase II Data at ASCO 2008 Annual Meeting |
| June 2 |
Data Presented at This Year's ASCO Meeting Provide New Insights
into the Treatment of Patients with Myelodysplastic Syndromes |
| June 2 |
Medivation Announces Presentation of Positive MDV3100 Clinical Data
in Castration-Resistant Prostate Cancer Patients at 44th ASCO
Annual Meeting |
| June 2 |
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented
at American Society of Clinical Oncology Annual Meeting |
| June 2 |
US Oncology Affiliated Physicians Make a Strong Showing in ASCO
Proceedings |
| June 2 |
Nimotuzumab Clinical Data Presented at ASCO Annual Meeting |
| June 2 |
Methylgene Reports Clinical Data for MGCD0103 at the 44th American
Society of Clinical Oncology (ASCO) Annual Meeting |
| June 2 |
Early Data Presented at ASCO Show Potential of RAD001 to Enhance
Efficacy of, and Overcome Resistance to, Breast Cancer Treatments |
| June 2 |
Investigational Studies Highlight Potential Utility of Zevalin
(Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell
Transplantation for Non-Hodgkin's Lymphoma |
| June 2 |
Early Data Presented at ASCO Show Potential of RAD001 To Enhance
Efficacy of, and Overcome Resistance to, Breast Cancer Treatments |
| June 2 |
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO
and Provides Clinical Update on Its Phase II Bavituximab Breast
Cancer Study |
| June 2 |
New Data from Several Satraplatin Clinical Trials in Solid Tumors
Presented at 44th ASCO Annual Meeting |
| June 2 |
Oncolytics Biotech Inc. Collaborators Present Positive Phase II
Sarcoma Trial Results at ASCO Annual Meeting |
| June 2 |
IDM Pharma Announces Data Supporting Improved Overall Survival
Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma
Treated with Mifamurtide (L-MTP-PE) |
| June 2 |
Leading Immunologists Convene in Boston |
| June 2 |
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy
and Safety of Clofarabine in Older Adult AML Patients |
| June 2 |
Vion Pharmaceuticals Announces Presentation of Interim Data from
Pivotal Phase II Trial of Cloretazine (VNP40101M) in Acute
Myelogenous Leukemia at the ASCO Annual Meeting |
| June 3 |
Trubion Announces Presentation of Positive TRU-016 Data at ASCO |
| June 3 |
ChemGenex Investigators Present Data on Clinical Activity of
Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients
with the T315I Mutation at ASCO |
| June 3 |
New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung
Cancer and Ewing's Sarcoma |
| June 3 |
Critical Therapeutics Completes Phase II Clinical Trial for
Zileuton Injection |
| June 3 |
Data from Studies of Amrubicin in Small-Cell Lung Cancer Presented
at the 2008 American Society of Clinical Oncology Meeting
Demonstrate Single Agent Anti-Tumor Activity in Western Patient
Population |
| June 3 |
Amylin Pharmaceuticals to Present Promising Data From Diabetes and
Obesity Programs at ADA 2008 |
| June 3 |
Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study
Results of R788 in Lymphoma |
| June 3 |
Analysis Showed No Increased Risk of Hospitalization in Patients
When Adding a LABA to ICS Compared to ICS Alone |
| June 3 |
ThromboGenics and BioInvent Report Positive Phase I Results for
Anti-PlGF Cancer Therapeutic TB-403 |
| June 3 |
Paclitaxel Poliglumex (Opaxio)/Capecitabine Regimen Well Tolerated
and Active in Metastatic Breast Cancer |
| June 3 |
ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the
American Society of Clinical Oncology (ASCO) |
| June 3 |
Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in
Diffuse Large B-Cell and SLL/CLL |
| June 3 |
Auxilium Pharmaceuticals, Inc. Announces Xiaflex Meets Primary
Endpoint With Statistical Significance (p<0.001) in CORD I
Pivotal Phase III Study for Dupuytren's Contracture |
| June 3 |
The Aethlon Hemopurifier Proves Effective in Capturing the
Reconstructed Spanish Flu of 1918 and H5N1 Avian Influenza Virus |
| June 3 |
The GI Company Reports Significant Reduction in Occurrence of Oral
Mucositis in Phase II Study Presented at ASCO |
| June 3 |
EntreMed Presents MKC-1 Phase 2 Data at American Society of
Clinical Oncology Annual Meeting |
| June 3 |
Tolerx Announces Data Presentations at American Diabetes
Association 68th Scientific Sessions 2008 |
| June 3 |
Study of Vidaza in Higher-Risk Myelodysplastic Syndrome Patients
Demonstrates Improved Overall Survival |
| June 3 |
Zysolin Shows Promising Results in Animal Study |
| June 3 |
NexMed Confirms Publication on Anti-Fungal Product |
| June 3 |
Isotechnika To Hold Conference Call to Discuss Positive PROMISE
Trial |
| June 3 |
Transgene’s Therapeutic Vaccine TG4010 Meets Primary Endpoint
Non-small Cell Lung Cancer Phase IIb Trial |
| June 3 |
Virax Co-X-Gene Technology Licence with Transgene Successful Phase
IIb trial Result for TG4010 in Non-Small Cell Lung Cancer |
| June 3 |
Altus Pharmaceuticals Reports ALTU-237 Phase 1 Clinical Trial
Results |
| June 3 |
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of
Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast
Cancer in a Phase 2 Trial |
| June 3 |
Seattle Genetics Reports Multiple Complete and Partial Responses
with SGN-35 in Patients with Lymphoma |
| June 3 |
ImmunoGen, Inc. Announces Presentation of Encouraging Clinical
Findings with Trastuzumab-DM1 at ASCO |
| June 3 |
New Ipilimumab Survival Data in Patients with Metastatic Melanoma
Presented at American Society of Clinical Oncology Annual Meeting |
| June 3 |
ImmunoGen, Inc. Announces Presentation of Encouraging Clinical
Findings with Trastuzumab-DM1 at ASCO |
| June 3 |
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on
KRX-0401 (Perifosine) in Patients with Relapsed/Refractory
Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the
American Society of Clinical Oncology |
| June 3 |
Immtech Announces Results From Hepatitis C Discovery Program |
| June 3 |
Generex Biotechnology Phase I Trial Results for Novel Immunotherapy
Vaccine in Breast Cancer Patients Presented at ASCO |
| June 3 |
On Matters of the Heart, Women Aged 40-plus Naive When It Comes to
Risks |
| June 3 |
New Modified Citrus Pectin Slows Cancer Progression and Stops
Cancer Cells in Their Tracks |
| June 3 |
AVAX Presents Results of a Dose-Response Study of MVax at American
Society of Clinical Oncology (ASCO) |
| June 3 |
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by
Target Tissues in the Eye |
| June 3 |
Promising Data on Head and Neck Cancer Announced by DNAR at 2008
American Society of Clinical Oncology Meeting |
| June 4 |
Reduced Hepatitis C Viral Level Achieved with DNA Vaccine Delivered
by Inovio Biomedical's Electroporation Delivery System in Phase
I/II Clinical Study |
| June 4 |
NanoViricides Inc. to Present at The NSTI Nanotech 2008 Conference
in Boston |
| June 4 |
Akesis Pharmaceuticals Completes Phase IIa Trial of AKP-020 for
Type 2 Diabetes |
| June 4 |
Celator Pharmaceuticals Announces Positive Phase 2 Results for
CPX-1 in Treatment of Colorectal Cancer |
| June 4 |
Sirtris Pharmaceuticals Presents at the American Diabetes
Association's 68th Annual Scientific Sessions June 8 |
| June 4 |
VIVUS Announces the Podium Presentation of Phase 2 Data for Qnexa
in Type 2 Diabetics at the American Diabetes Association Meeting |
| June 4 |
Isotechnika Presents Positive Data from the Promise Trial of
Voclosporin at the American Transplant Congress |
| June 4 |
Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA
Conference |
| June 4 |
Intravenous Iron May Help Treat Anemia in Patients with Kidney
Disease |
| June 4 |
Somaxon Pharmaceuticals to Present Data at the 22nd Annual Meeting
of the Associated Professional Sleep Societies |
| June 4 |
Semafore Pharmaceuticals Reports Positive Interim Results from a
Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients
with Advanced Solid Tumors |
| June 4 |
Interim Phase 2 Results on Prospect Therapeutics' GCS-100 Presented
at the 10th International Conference on Malignant Lymphoma |
| June 4 |
Transcept Pharmaceuticals Announces Intent to Submit New Drug
Application for Intermezzo in Third Quarter 2008 |
| June 4 |
CellCept and a Reduced Level of CNI Shows Trend Towards
Preservation of Kidney Function Versus a Standard-Dose CNI |
| June 4 |
World's Leading Health Experts Urge Countries to Use Newly Released
Data to Prevent the Death of Millions of Children Due to Rotavirus |
| June 4 |
New Diabetes Research To Be Presented at FOCIS Annual Meeting |
| June 4 |
World's Leading Health Experts Urge Countries to Use Newly Released
Data to Prevent the Death of Millions of Children Due to Rotavirus |
| June 4 |
Racial Disparities in the Outcomes of Patients with Chronic Kidney
Disease Abound |
| June 5 |
Promise of Vical's CMV Vaccine Noted by Independent Experts |
| June 5 |
Inovio Biomedical Provides Updated Interim Data on Phase I/II
Clinical Study of Electroporation-Delivered Prostate Cancer DNA
Vaccine at ASGT Annual Meeting |
| June 5 |
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates
Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma |
| June 5 |
Novel Investigational Regimen Combining Radiation Enhancing Agent
With Ibritumomab Tiuxetan (Zevalin) Produces High Rate of Complete
Responses in Patients With Rituximab-Refractory Follicular
Non-Hodgkin's Lymphoma |
| June 5 |
Regado Biosciences Announces Publication in Circulation of Clinical
Trial Results of REG1 Anticoagulation System |
| June 5 |
Arana Therapeutics Completes Second Project with CSL |
| June 5 |
Positive Clinical Data Evaluating the Micrus Endovascular Cerecyte
Microcoil Published in Peer-Reviewed Journals |
| June 5 |
SemBioSys Demonstrates Functionality of its Safflower Produced Apo
AI(Milano) |
| June 5 |
Ardea to Present Data on Inflammation Programs at 2008 Annual
European Congress of Rheumatology |
| June 5 |
MacroChem Announces Presentation by Michael Zasloff, MD, PhD on
Topical Therapy for Diabetic Foot Infection |
| June 5 |
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted
Radiation Therapy Demonstrates High Complete Response Rate in
Patients With Non-Hodgkin's Lymphoma |
| June 5 |
Nuvelo Announces Publication of Preclinical Data From Wnt
Therapeutics Program |
| June 5 |
Senesco Expands on Preclinical Multiple Myeloma Findings |
| June 5 |
Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma
Data at International Conference on Malignant Lymphoma |
| June 5 |
Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma
Data at International Conference on Malignant Lymphoma |
| June 5 |
New Data Show Potential of Rasilez to Protect Kidneys from Damage
Independent of Its Proven Ability to Lower Blood Pressure |
| June 5 |
Study Supports Possible Use of Leukine as a Potential Adjuvant
Therapy for High-Risk Melanoma Patients |
| June 5 |
Gloucester Pharmaceuticals Announces Podium Presentation of
Positive Results from Phase 2b Registration Trial of Romidepsin in
Refractory CTCL |
| June 5 |
Monotherapy Reveals Significant Biological Activity without
Toxicity in Chemo-Resistant Metastatic Breast Cancer |
| June 6 |
TriMix Gel Achieves Success Among Men Who Have Failed to Achieve
Erections With Viagra, Levitra and Cialis Type Tablets |
| June 6 |
Allos Therapeutics Announces Interim Data from Phase 1 Study of PDX
in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma |
| June 6 |
T3Therapeutics, LLC and Archimedes Pharma Ltd Announce Positive
Clinical Results for Novel Oral Modified Release Liothyronine |
| June 6 |
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial
with Denufosol for Cystic Fibrosis |
| June 6 |
Genelabs Technologies Announces Presentation of Data on
Non-Nucleoside HCV Polymerase Inhibitor at 3rd International
Workshop on Hepatitis C, Resistance and New Compounds |
| June 6 |
Seattle Genetics Announces SGN-35 Plenary Presentation at
International Conference on Malignant Lymphoma |
| June 6 |
Brain Stem Cells Can Be Awakened, Say Schepens Scientists |
| June 6 |
Synvista Therapeutics Reports Results of Three Phase 2 Clinical
Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease |
| June 6 |
CONTRAST Study: To What Extent Do High-Risk Patients Benefit From
the Renal Tolerance of Iso-Osmolar X-Ray Contrast Media? |
| June 9 |
ImmuneRegen BioSciences Confirms Adult Stem Cell Activity of
Homspera in Human Bone Marrow |
| June 9 |
Repros Therapeutics Inc. Announces That Initial Findings for
Proellex Show No Gross Cancer Tumors in First Completed Animal
Carcinogenicity Study |
| June 9 |
Achillion Announces Additional Positive Top-Line Phase 2 Data for
Elvucitabine |
| June 9 |
Accord Clinical Trial Publishes Results |
| June 9 |
Abbott's Phase III Sub-Group Analysis Shows Investigational
TriLipix in Combination with Crestor Improves Key Lipids in
Patients with Mixed Dyslipidemia and Type 2 Diabetes |
| June 9 |
Onglyza (saxagliptin) Demonstrated Significant Reductions in Key
Measures of Glucose Control in Treatment Naive People with Type 2
Diabetes |
| June 9 |
NanoViricides Inc. Posts Photos Showing Rapid Response of Animals
to Treatment with EKC Eye Drug Candidate |
| June 9 |
Hollis-Eden Pharmaceuticals Reports Additional Positive Data from
Phase I/II Clinical Trial with Triolex Supporting Anti-Inflammatory
Approach to Treating Type 2 Diabetes |
| June 9 |
Nastech Announces Positive Intranasal Insulin Data at American
Diabetes Association Meeting |
| June 9 |
Cerus Announces INTERCEPT Blood System Data Presented at
International Society of Blood Transfusion Conference Support Broad
Utility in Safeguarding the Blood Supply |
| June 9 |
Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical
Models of Rheumatoid Arthritis and Lymphoma |
| June 9 |
Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based
Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior
Treatment |
| June 9 |
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin) Regimen
Produces Impressive Survival Rates in High Risk Elderly Patients
With Untreated Aggressive Diffuse Large B-cell Lymphoma |
| June 9 |
Arisaph Pharmaceuticals Announces at the ADA that Its Potent DPP 4
Inhibitor (ARI-2243) Possesses an Additional Mechanism that
Contributes to Improved Glucose Control |
| June 9 |
Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3
Investigational Diabetes Therapy, Showed Improvements in Glycemic
Control, Weight |
| June 9 |
Elixir Pharmaceuticals Announces New Data at the 2008 American
Diabetes Association Annual Meeting |
| June 9 |
Sangamo BioSciences Announces Presentation of Phase 1b ZFP
Therapeutic Data at American Diabetes Association Meeting |
| June 9 |
Data from Phase II Clinical Trial of Galiximab in Combination with
Rituximab in Patients with Previously Untreated Follicular Lymphoma
Presented at International Conference on Malignant Lymphoma |
| June 9 |
Generex Biotechnology Presented Data At American Diabetes
Association Scientific Sessions |
| June 9 |
Genaera Corporation Presents Additional Promising Preclinical Type
2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes
Association |
| June 9 |
Nastech Announces Positive Intranasal Insulin Data at American
Diabetes Association Meeting |
| June 9 |
Halozyme Therapeutics Announces Phase I Clinical Trial Results
Demonstrating that the Combination of Recombinant Human
Hyaluronidase (rHuPH20) With Humulin R and with Humalog Yields
Faster, More Physiologic Insulin Kinetics and Better Predictability |
| June 9 |
Video: Clinical Study Shows Liraglutide Reduced Blood Sugar,
Weight, and Blood Pressure in Patients with Type 2 Diabetes |
| June 9 |
Biopure Responds to JAMA and Meta-Analysis |
| June 9 |
Idera Pharmaceuticals Presents Preclinical Data of Toll-Like
Receptor Antagonists in Models of Lung Inflammation and Psoriasis |
| June 9 |
A New Analysis Released at ADA: Lower Risk of Symptomatic
Hypoglycemia with Januvia (sitagliptin) Compared to Glipizide on a
Background of Metformin in Patients with Type 2 Diabetes |
| June 9 |
Lipid Sciences' Autologous Therapeutic HIV Vaccine Study Published
in "Experimental Biology and Medicine" |
| June 9 |
Kamada Announces Successful Interim Results of Phase II Deposition
Study with Aerosolized AAT |
| June 9 |
Hollis-Eden Pharmaceuticals Reports Additional Positive Data from
Phase I/II Clinical Trial with Triolex Supporting Anti-Inflammatory
Approach to Treating Type 2 Diabetes |
| June 9 |
New Discovery of Key Difference in Bile Acid Metabolism in Patients
with Type 2 Diabetes May Suggest Underlying Disorder |
| June 9 |
CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at
Prestigious Immunology Conference |
| June 9 |
Four Independent Research Groups Present Data Generated by Pressure
Cycling Technology (PCT) at the ASMS Conference on Mass
Spectrometry and Allied Topics in Denver, CO |
| June 10 |
Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at
ADA Conference |
| June 10 |
Alexza Announces Preliminary Results From its AZ-002 (Staccato
Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic
Disorder |
| June 10 |
OSI Pharmaceuticals Presents Diabetes/Obesity Preclinical
Compounds, PSN821 and PSN602, at Annual Meeting of the American
Diabetes Association |
| June 10 |
Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide,
into Phase III Clinical Trials |
| June 10 |
Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and
Blood Pressure in Patients with Type 2 |
| June 10 |
Use of Mealtime Symlin Compared to Rapid-Acting Insulin for
Diabetes Therapy Intensification in Patients With Type 2 Diabetes
Using Basal Insulin |
| June 10 |
Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates
Improvements in Insulin Sensitivity and Lowers Cholesterol Levels
in Type 2 Diabetics |
| June 10 |
Schizophrenia: Twice as Common as HIV/AIDS, but Survey Shows
Americans Misinformed |
| June 10 |
After One Year, Type 2 Diabetes Patients Taking Exenatide Once
Weekly Sustained Improvements in Glycemic Control and Weight;
DURATION-1 Presented at ADA 2008 |
| June 10 |
High-dose Immunosuppressant Drug Appears to Reduce Disease Activity
and Disability in Patients with Multiple Sclerosis |
| June 10 |
NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy
Study Results in Neurology |
| June 10 |
Acomplia (rimonabant) Significantly Improved Glucose Control in
Type 2 Diabetes Patients Treated with Insulin |
| June 10 |
Five-Year Safety Study Examines the Effect of LANTUS® on the
Progression of Retinopathy in People with Type 2 Diabetes |
| June 10 |
Metabasis Presents Preclinical Results for MB07803, Its Product
Candidate for Type 2 Diabetes, and Its Glucagon Antagonist Program
at the American Diabetes Association Meeting |
| June 10 |
Video: Clinical Study Shows Liraglutide Reduced Blood Sugar,
Weight, and Blood Pressure in Patients with Type 2 Diabetes |
| June 10 |
Results From One-Year Study Suggest Advair Provides Important
Benefits for African American Patients With Asthma |
| June 10 |
Qnexa Reduces Hemoglobin A1c by 1.2 Percent in 28 Weeks |
| June 10 |
After One Year, Type 2 Diabetes Patients Taking Exenatide Once
Weekly Sustained Improvements in Glycemic Control and Weight;
DURATION-1 Presented at ADA 2008 |
| June 10 |
Ambien CR (zolpidem tartrate extended-release) CIV Tablets Improved
Insomnia and Daily Functioning in Patients with Co-Morbid Major
Depressive Disorder |
| June 10 |
Array BioPharma to Present Clinical Data at the 2008 Annual
European Congress of Rheumatology |
| June 11 |
Biopure Phase III Orthopedic Trial Results Published in Journal of
Trauma |
| June 11 |
Biovest Reports Blinded Results for Phase 3 Study Evaluating
Anti-Cancer Vaccine, BiovaxID, which Shows 100% Difference in
Disease-Free Survival at 36 Months in the Comparative Arms |
| June 11 |
Biovest Reports Blinded Results for Phase 3 Study Evaluating
Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in
Disease-Free Survival at 36 Months in the Comparative Arms |
| June 11 |
Panacos Presents Bevirimat Patient Response Predictors at the
International HIV Drug Resistance Workshop |
| June 11 |
Pierre Fabre Medicament Announces Submission of a Market
Authorization Application for Milnacipran in Europe : New Data from
European Phase III Fibromyalgia Study presented at EULAR congress |
| June 11 |
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly
Improved Signs and Symptoms of Rheumatoid Arthritis |
| June 11 |
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in
Melanoma |
| June 11 |
New evidence shows MabThera is more effective than a second TNF
inhibitor in rheumatoid arthritis patients who have interrupted
anti-TNF therapy due to lack of efficacy |
| June 11 |
New potential application for SUBA-Itraconazole in oncology |
| June 11 |
Phase 3 Data Show Efficacy of Golimumab in Patients with Active
Rheumatoid Arthritis Previously Treated with Anti-TNF Agents |
| June 11 |
Ardea Biosciences Presents Inflammation Program Data for Arthritis
and Gout at 2008 Annual European Congress of Rheumatology |
| June 11 |
Diabetes Experts Respond to New Clinical Trials |
| June 11 |
Optimer to Present Additional Data from OPT-80 Phase 2A Study for
Clostridium difficile Infection at Anaerobe 2008 Congress |
| June 11 |
New Meta-Analysis Confirms Safety Profile for NeoRecormon in
Treating Anaemia in Cancer Patients |
| June 11 |
Novo Nordisk Discontinues Phase 3 Clinical Trial with Novoseven in
Trauma |
| June 11 |
Interim Results for the Zilver PTX Clinical Study from Cook Medical
Show Promise for Improving the Treatment of Blockages in the
Femoropopliteal Artery |
| June 11 |
Intermezzo 3.5 mg Achieves Greater Early Bioavailability Than
Ambien 10 mg Despite 65% Lower Dose |
| June 11 |
Angiotech's Corporate Partner, Cook Medical, Announces Positive
Interim Results for its Zilver PTX Clinical Study |
| June 11 |
MTR106 Tablets Were Found to be Effective in Acute Migraine Attacks |
| June 12 |
Human Genome Sciences Reports Positive Long-Term Data for
LymphoStat-B in Patients With Active Systemic Lupus Erythematosus |
| June 12 |
Incyte to Host EULAR Webcast and Conference Call on June 12 |
| June 12 |
Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in
Phase IIa Rheumatoid Arthritis Study |
| June 12 |
Promising Data Presented on GenVec Malaria Vaccine Program |
| June 12 |
Dermatologic Surgery Journal Publishes Comparison of Global
PMMA-Based Dermal Fillers Showing Superior Characteristics of
ArteFill Microspheres |
| June 12 |
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free
Survival as Predictor of Improved Overall Survival |
| June 12 |
Iomai Announces Publication in The Lancet of Phase II Study
Demonstrating Significant Efficacy of Travelers’ Diarrhea
Vaccine |
| June 12 |
The New England Journal of Medicine Publishes Study Investigating
the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu
Vaccine |
| June 12 |
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data
Presented at Annual European Congress of Rheumatology |
| June 12 |
Ambrilia Biopharma Presents New HIV Integrase Inhibitors |
| June 12 |
Iomai Announces Publication in The Lancet of Phase II Study
Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine |
| June 12 |
Geron Presents Data at ISSCR Showing That Its Embryonic Stem Cell
Therapeutic for Heart Failure Evades Direct Attack by the Human
Immune System |
| June 12 |
Pharmaxis Long-Term Safety Study of Bronchitol Completes |
| June 12 |
Positive Phase I/II Data of IDX899 Confirm Potent Antiviral
Activity and Favorable Safety Profile in Treatment-Naive
HIV-Infected Patients |
| June 12 |
BioSante Pharmaceuticals VP of Clinical Development To Present at
The Endocrine Society's 90th Annual Meeting |
| June 12 |
Tengion Scientists Publish Key Preclinical Findings Demonstrating
the Benefits of Organ Regeneration Vs. Repair |
| June 12 |
Orencia (abatacept) Provided an Increasing Degree of Inhibition of
Structural Damage Through Three Years in Adults with Moderate to
Severe Rheumatoid Arthritis |
| June 12 |
Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II
Retreatment Studies of Tovaxin for Multiple Sclerosis |
| June 12 |
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial
Results of APD125 for the Treatment of Insomnia at 22nd Annual
Meeting of the Associated Professional Sleep Societies |
| June 12 |
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial
Results of APD125 for the Treatment of Insomnia at 22nd Annual
Meeting of the Associated Professional Sleep Societies |
| June 12 |
PTC Therapeutics Announces Data from Additional Clinical Studies of
PTC124 in Cystic Fibrosis Confirming Activity |
| June 12 |
Tumor Targeting Docetaxel Abstract Selected for Presentation at the
11th Liposome Research Days Conference |
| June 12 |
SILENOR Data Presented at the 22nd Annual Meeting of the Associated
Professional Sleep Societies |
| June 12 |
At Least 50% of Recent Onset Rheumatoid Arthritis Patients Become
Free of Signs and Symptoms Within 36 Weeks |
| June 12 |
New Self-Management Programme Offers Significant Benefits for
Arthritis Patients with Chronic Pain |
| June 12 |
Inspire's Phase 3 CF Trial, Using PARI's Nebulizer &
Compressor, Shows Positive Top-Line Results |
| June 12 |
Adalimumab Therapy Effective in Ankylosing Spondylitis, Rheumatoid
Arthritis and Psoriatic Arthritis Patients Refractory to Other
Anti-tnf Therapies |
| June 12 |
Hand Bone Mineral Density is an Effective Predictor of Mortality in
Rheumatoid Arthritis |
| June 12 |
Ovarian Function and Fertility Preserved in Women with Severe
Systemic Lupus Erythematosus Through Treatment with
Cyclophosphamide and Mycophenolate Mofetil |
| June 13 |
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for
Naproxcinod at EULAR |
| June 13 |
Acterma (tocilizumab) Significantly Reduces Rheumatoid Arthritis
Signs and Symptoms Regardless of Previous Therapy in Two New Global
Studies |
| June 13 |
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine
(VNP40101M) in Elderly Patients with High-Risk Myelodysplastic
Syndromes at the EHA Annual Meeting |
| June 13 |
New Long-Term Humira (adalimumab) Data Show Up to Seven-Year
Efficacy with Combination Treatment for Rheumatoid Arthritis |
| June 13 |
Humira (adalimumab) Data Show That Treating Early Rheumatoid
Arthritis With Combination Treatment Resulted in Cost Savings From
Improved Work Productivity |
| June 13 |
Data Show that Abbott's Humira (adalimumab) Reduced the Signs and
Symptoms of Ankylosing Spondylitis Up to Three Years |
| June 13 |
Array BioPharma Presents Additional Positive Phase 1 Results in Two
Programs at the 2008 Annual European Congress of Rheumatology |
| June 13 |
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for
Naproxcinod at EULAR |
| June 13 |
New data: Actemra the first and only biologic to show superiority
over current standard of care in RA |
| June 13 |
Higher Initial Dose of Glivec Achieved Better Early Responses Than
Standard Dose for Patients with Chronic Myeloid Leukemia |
| June 13 |
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of
Osteoarthritis of the Knee in New Study |
| June 13 |
Array BioPharma Presents Additional Positive Phase 1 Results in Two
Programs at the 2008 Annual European Congress of Rheumatology |
| June 13 |
Carbocisteine Can Reduce Worsening of COPD |
| June 13 |
Gilead Announces Interim 12-Month Phase III Study Results for
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis |
| June 13 |
Video: Higher Initial Dose of Gleevec Achieved Better Early
Responses than Standard Dose for Patients with Chronic Myeloid
Leukemia |
| June 13 |
VIVUS Announces Presentation of Qnexa Data at the 2008 BIO
International Convention |
| June 13 |
Transave Announces Positive Phase II Results for Once-Daily Arikace
in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas
Lung Infections |
| June 13 |
SIR-Spheres Microspheres Featured at the 2008 Society of Nuclear
Medicine Annual Meeting |
| June 13 |
Exelixis Presents Clinical Data Supporting the Safety and Initial
Clinical Activity of XL228 in Chronic and Acute Leukemia |
| June 13 |
SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression
in AML Xenograft Models |
| June 13 |
Study of Vidaza in Higher-Risk Patients with Myelodysplastic
Syndromes Reports Improved Overall Survival |
| June 13 |
Vidaza Continues to Show Significant Overall Survival Benefit When
Compared with Conventional Care Regimens Across the EU |
| June 13 |
Data from Phase II Exploratory Study Suggest That Orencia
(abatacept) May Delay Development of Rheumatoid Arthritis in Adults
with Undifferentiated Inflammatory Arthritis |
| June 13 |
Data Presented at the 13th Congress of the European Hematology
Association Demonstrate Advances in the Treatment of Patients with
High-Risk Myelodysplastic Syndromes |
| June 16 |
Vical Pandemic Influenza Vaccines Provide Complete Protection in
Animal Studies; The Journal of Infectious Diseases Publishes H5N1
Challenge Data |
| June 16 |
NanoViricides Anti-HIV Lead Drug Candidate Demonstrated Substantial
Improvement in Survival Time in Animal Model |
| June 16 |
Antisoma plc (UK) - Antisoma announces AS1413 (Xanafide)
presentation at EHA |
| June 16 |
Bionovo Discovers New Estrogen Regulatory Elements for Breast
Cancer and Osteoporosis Drugs |
| June 16 |
ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb
Schizophrenia Trial |
| June 16 |
ChemGenex’s Omacetaxine Demonstrates Activity in CML Patients
Who Have Failed Therapy with Multiple Tyrosine Kinase Inhibitors |
| June 16 |
Soliris Improved Fatigue Independent of Changes in Anemia in
Patients with PNH by Controlling Hemolysis |
| June 16 |
Romiplostim Data Show Potential Long-Term Efficacy and Safety in
Adults with Chronic ITP |
| June 16 |
Sunesis Pharmaceuticals Presents Data from Clinical Trials of
Voreloxin (formerly SNS-595) in Patients with Acute Myeloid
Leukemia at the 13th Congress of the European Hematology
Association |
| June 16 |
Adventrx Announces CoFactor Phase 2b Clinical Trial Overall
Survival Results |
| June 16 |
SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell
Proliferation |
| June 16 |
Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on
Neural Pathways Related to Temperature Regulation |
| June 16 |
Teva's Azilect 1 mg Tablets Meet End Points in ADAGIO Phase III
Trial |
| June 16 |
ChemGenex's Omacetaxine Demonstrates Activity in CML Patients Who
Have Failed Therapy With Multiple Tyrosine Kinase Inhibitors |
| June 16 |
Gentronix Use Abcellute Preserved Hepatocytes to Enhance in Vitro
Genotoxicity Testing |
| June 16 |
Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at
the International Society for Stem Cell Research Annual Meeting |
| June 16 |
Sensitivity Enhancements to Monogram's Trofile Assay Demonstrate
Improved Power to Select Patients for CCR5 Antagonist Therapy |
| June 16 |
Bionovo's Drug Candidate Shows In Vivo Safety and Efficacy in the
Treatment of Vaginal Atrophy |
| June 16 |
Nextrials and Allon Therapeutics Set New Benchmark for Releasing
Clinical Trial Results |
| June 16 |
Journal of Drugs in Dermatology Highlights Data Showing the
Benefits of Solubilized 5% Benzoyl Peroxide Gel in the Treatment of
Acne |
| June 16 |
Molecular Insight Pharmaceuticals, Inc. Reports Preclinical Data on
Solazed for Treatment of Metastatic Melanoma at Society of Nuclear
Medicine (SNM) Meeting |
| June 16 |
Novelos Therapeutics and MUSC Peer Reviewed Article Published in
Expert Opinion on Investigational Drugs |
| June 16 |
Quatrx Pharmaceuticals Presents Results From Ophena (Ospemifene
Tablets) Phase 3 Study Related to Treatment of Symptoms of
Vulvovaginal Atrophy |
| June 16 |
Neuromonics Announces Publication of Controlled Tinnitus Treatment
Study |
| June 16 |
US WorldMeds Completes Phase III Trial of Lofexidine for Treatment
of Opiate Withdrawal Symptoms |
| June 16 |
Data from Overseas Phase III Trial (RADIATE and AMBITION)
Demonstrates Efficacy of "Actemra," a Humanized Anti-Human IL-6
Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients |
| June 16 |
New Study Shows Benicar (olmesartan medoxomil) Reverses Blood
Vessel Damage Independent of Blood Pressure Lowering |
| June 16 |
Revlimid Data for Newly Diagnosed Multiple Myeloma Reported at a
Satellite Symposium During the 13th European Hematology Association
Congress |
| June 16 |
VaxInnate to Discuss Seasonal and Pandemic Flu Vaccines During BIO
2008 This Week |
| June 16 |
More Than Two-Thirds of Newly-Diagnosed Patients Who Are Prescribed
Medications for OCD Receive Inadequate Therapy |
| June 16 |
Pharming announces positive results from North American randomized
trial with rhucin |
| June 16 |
Tercica Announces Results from Increlex IGFD Patient Registry and
Other Increlex Studies at the 90th Meeting of the Endocrine Society |
| June 16 |
BaroFold Inc. Initiates First Human Studies for Multiple Sclerosis
Drug Candidate, BaroFeron |
| June 16 |
Preterax Prevents / Regresses Kidney Disease in Diabetics in
Addition to Life-saving Benefits |
| June 17 |
Akesis Pharmaceuticals Reports Positive Results from its Phase IIa
Trial of AKP-020 for Type 2 Diabetes |
| June 17 |
Trubion Pharmaceuticals Announces Presentation of Positive TRU-015
and SBI-087 Data at the 2008 Annual European Congress of
Rheumatology Meeting |
| June 17 |
Elan and Wyeth Announce Encouraging Top-line Results from Phase 2
Clinical Trial of Bapineuzumab for Alzheimer's Disease |
| June 17 |
Clinical Data For Revlimid And Vidaza In Important Blood Cancers
Presented at The 13th European Hematology Association Congress |
| June 17 |
PLx Pharma Demonstrates Bioequivalence with Aspirin and PL 2100 --
Aspirin-PC |
